Prediction of disease-free survival in patients with squamous cell carcinomas of the head and neck using dynamic contrast-enhanced MR imaging

S. Chawla, S. Kim, L. A. Loevner, W. T. Hwang, G. Weinstein, A. Chalian, Harry Quon, Harish Poptani

Research output: Contribution to journalArticle

Abstract

BACKGROUND AND PURPOSE: Patients with HNSCC have a poor prognosis and development of imaging biomarkers that predict long-term outcome might aid in planning optimal treatment strategies. Therefore, the purpose of the present study was to predict disease-free survival in patients with HNSCC by using pretreatment Ktrans measured from dynamic contrast-enhanced MR imaging. MATERIALS AND METHODS: Sixty-six patients with HNSCC were recruited from January 2005 to October 2008. Three patients were excluded because they underwent upfront neck dissection, and 6 patients were excluded due to suboptimal MR imaging data or being lost to follow-up. Disease-free survival was measured in the remaining 57 patients from the end date of chemoradiation therapy. In patients who died, the end point was the date of death, while in surviving patients the date of last clinical follow-up was used as the end point. Pretreatment Ktrans and nodal volume were computed from the largest metastatic node, and median pretreatment Ktrans and volume were used to divide patients into 2 groups (at or above the threshold value [group I] and below the threshold value [group II]. Disease-free survival was analyzed by the Kaplan-Meier method, and the results were compared by using a logrank test with Ktrans and nodal volume as predictors. A P value <.05 was considered significant. RESULTS: Thirteen of 57 patients had died of HNSCC by the last follow-up period (March 31, 2009). Patients with higher pretreatment Ktrans values had prolonged disease-free survival compared with patients with lower Ktrans values (P = .029). However, there was no significant difference in disease-free survival when nodal volume was used as a predictor (P = .599). CONCLUSIONS: Pretreatment Ktrans may be a useful prognostic marker in HNSCC.

Original languageEnglish (US)
Pages (from-to)778-784
Number of pages7
JournalAmerican Journal of Neuroradiology
Volume32
Issue number4
DOIs
StatePublished - Apr 2011
Externally publishedYes

Fingerprint

Disease-Free Survival
Carcinoma, squamous cell of head and neck
Neck Dissection
Lost to Follow-Up
Biomarkers

ASJC Scopus subject areas

  • Clinical Neurology
  • Radiology Nuclear Medicine and imaging

Cite this

Prediction of disease-free survival in patients with squamous cell carcinomas of the head and neck using dynamic contrast-enhanced MR imaging. / Chawla, S.; Kim, S.; Loevner, L. A.; Hwang, W. T.; Weinstein, G.; Chalian, A.; Quon, Harry; Poptani, Harish.

In: American Journal of Neuroradiology, Vol. 32, No. 4, 04.2011, p. 778-784.

Research output: Contribution to journalArticle

Chawla, S. ; Kim, S. ; Loevner, L. A. ; Hwang, W. T. ; Weinstein, G. ; Chalian, A. ; Quon, Harry ; Poptani, Harish. / Prediction of disease-free survival in patients with squamous cell carcinomas of the head and neck using dynamic contrast-enhanced MR imaging. In: American Journal of Neuroradiology. 2011 ; Vol. 32, No. 4. pp. 778-784.
@article{48a2736fe2564df08ad3c9cb3ad07b5e,
title = "Prediction of disease-free survival in patients with squamous cell carcinomas of the head and neck using dynamic contrast-enhanced MR imaging",
abstract = "BACKGROUND AND PURPOSE: Patients with HNSCC have a poor prognosis and development of imaging biomarkers that predict long-term outcome might aid in planning optimal treatment strategies. Therefore, the purpose of the present study was to predict disease-free survival in patients with HNSCC by using pretreatment Ktrans measured from dynamic contrast-enhanced MR imaging. MATERIALS AND METHODS: Sixty-six patients with HNSCC were recruited from January 2005 to October 2008. Three patients were excluded because they underwent upfront neck dissection, and 6 patients were excluded due to suboptimal MR imaging data or being lost to follow-up. Disease-free survival was measured in the remaining 57 patients from the end date of chemoradiation therapy. In patients who died, the end point was the date of death, while in surviving patients the date of last clinical follow-up was used as the end point. Pretreatment Ktrans and nodal volume were computed from the largest metastatic node, and median pretreatment Ktrans and volume were used to divide patients into 2 groups (at or above the threshold value [group I] and below the threshold value [group II]. Disease-free survival was analyzed by the Kaplan-Meier method, and the results were compared by using a logrank test with Ktrans and nodal volume as predictors. A P value <.05 was considered significant. RESULTS: Thirteen of 57 patients had died of HNSCC by the last follow-up period (March 31, 2009). Patients with higher pretreatment Ktrans values had prolonged disease-free survival compared with patients with lower Ktrans values (P = .029). However, there was no significant difference in disease-free survival when nodal volume was used as a predictor (P = .599). CONCLUSIONS: Pretreatment Ktrans may be a useful prognostic marker in HNSCC.",
author = "S. Chawla and S. Kim and Loevner, {L. A.} and Hwang, {W. T.} and G. Weinstein and A. Chalian and Harry Quon and Harish Poptani",
year = "2011",
month = "4",
doi = "10.3174/ajnr.A2376",
language = "English (US)",
volume = "32",
pages = "778--784",
journal = "American Journal of Neuroradiology",
issn = "0195-6108",
publisher = "American Society of Neuroradiology",
number = "4",

}

TY - JOUR

T1 - Prediction of disease-free survival in patients with squamous cell carcinomas of the head and neck using dynamic contrast-enhanced MR imaging

AU - Chawla, S.

AU - Kim, S.

AU - Loevner, L. A.

AU - Hwang, W. T.

AU - Weinstein, G.

AU - Chalian, A.

AU - Quon, Harry

AU - Poptani, Harish

PY - 2011/4

Y1 - 2011/4

N2 - BACKGROUND AND PURPOSE: Patients with HNSCC have a poor prognosis and development of imaging biomarkers that predict long-term outcome might aid in planning optimal treatment strategies. Therefore, the purpose of the present study was to predict disease-free survival in patients with HNSCC by using pretreatment Ktrans measured from dynamic contrast-enhanced MR imaging. MATERIALS AND METHODS: Sixty-six patients with HNSCC were recruited from January 2005 to October 2008. Three patients were excluded because they underwent upfront neck dissection, and 6 patients were excluded due to suboptimal MR imaging data or being lost to follow-up. Disease-free survival was measured in the remaining 57 patients from the end date of chemoradiation therapy. In patients who died, the end point was the date of death, while in surviving patients the date of last clinical follow-up was used as the end point. Pretreatment Ktrans and nodal volume were computed from the largest metastatic node, and median pretreatment Ktrans and volume were used to divide patients into 2 groups (at or above the threshold value [group I] and below the threshold value [group II]. Disease-free survival was analyzed by the Kaplan-Meier method, and the results were compared by using a logrank test with Ktrans and nodal volume as predictors. A P value <.05 was considered significant. RESULTS: Thirteen of 57 patients had died of HNSCC by the last follow-up period (March 31, 2009). Patients with higher pretreatment Ktrans values had prolonged disease-free survival compared with patients with lower Ktrans values (P = .029). However, there was no significant difference in disease-free survival when nodal volume was used as a predictor (P = .599). CONCLUSIONS: Pretreatment Ktrans may be a useful prognostic marker in HNSCC.

AB - BACKGROUND AND PURPOSE: Patients with HNSCC have a poor prognosis and development of imaging biomarkers that predict long-term outcome might aid in planning optimal treatment strategies. Therefore, the purpose of the present study was to predict disease-free survival in patients with HNSCC by using pretreatment Ktrans measured from dynamic contrast-enhanced MR imaging. MATERIALS AND METHODS: Sixty-six patients with HNSCC were recruited from January 2005 to October 2008. Three patients were excluded because they underwent upfront neck dissection, and 6 patients were excluded due to suboptimal MR imaging data or being lost to follow-up. Disease-free survival was measured in the remaining 57 patients from the end date of chemoradiation therapy. In patients who died, the end point was the date of death, while in surviving patients the date of last clinical follow-up was used as the end point. Pretreatment Ktrans and nodal volume were computed from the largest metastatic node, and median pretreatment Ktrans and volume were used to divide patients into 2 groups (at or above the threshold value [group I] and below the threshold value [group II]. Disease-free survival was analyzed by the Kaplan-Meier method, and the results were compared by using a logrank test with Ktrans and nodal volume as predictors. A P value <.05 was considered significant. RESULTS: Thirteen of 57 patients had died of HNSCC by the last follow-up period (March 31, 2009). Patients with higher pretreatment Ktrans values had prolonged disease-free survival compared with patients with lower Ktrans values (P = .029). However, there was no significant difference in disease-free survival when nodal volume was used as a predictor (P = .599). CONCLUSIONS: Pretreatment Ktrans may be a useful prognostic marker in HNSCC.

UR - http://www.scopus.com/inward/record.url?scp=79954544024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954544024&partnerID=8YFLogxK

U2 - 10.3174/ajnr.A2376

DO - 10.3174/ajnr.A2376

M3 - Article

VL - 32

SP - 778

EP - 784

JO - American Journal of Neuroradiology

JF - American Journal of Neuroradiology

SN - 0195-6108

IS - 4

ER -